Dicerna Pharmaceuticals Inc. (DRNA) Stock Price Down 2.8%
Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded down 2.8% during mid-day trading on Thursday . The company traded as low as $3.45 and last traded at $3.49, with a volume of 244,056 shares trading hands. The stock had previously closed at $3.59.
A number of equities research analysts have issued reports on the company. Jefferies Group restated a “buy” rating and set a $19.00 price objective (down from $25.00) on shares of Dicerna Pharmaceuticals in a research report on Saturday, March 12th. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Chardan Capital decreased their price objective on Dicerna Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, June 30th. Stifel Nicolaus decreased their price objective on Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, June 30th. Finally, Leerink Swann restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $11.95.
The firm’s market cap is $73.37 million. The firm has a 50 day moving average of $3.48 and a 200 day moving average of $5.54.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.10. Analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.34) EPS for the current year.
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.